R&D Pipeline

 

Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.

 

Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.

Oncology

Target
Indication
Drug Candidate

HPK1

Oncology

FB849 / Discovery

HPK1 TIL Therapy

Oncology (Cell Therapy)

TIL Therapy / Discovery

GCN2

Oncology

1ST-206 / Discovery

Novel ADC payload1

Oncology

1ST-EP1 / Discovery

Novel ADC payload2

Oncology

1ST-EP2 / Discovery
Discovery
Preclinical
Phase 1

Neurodegenerative Diseases

Target
Indication
Drug Candidate

c-Abl

ALS, Parkinson’s

FB-101 / Discovery

c-Abl/LRRK2

Parkinson’s, ALS

FB418 / Discovery

c-Abl/PET

PET tracer for c-Abl therapeutic

FB610 / Discovery

LRRK2

Parkinson’s

1ST-107 / Discovery

Undisclosed

Neurological rare disease

1ST-106 / Discovery
Discovery
Preclinical
Phase 1

Platform Technology

PROJECT
PLATFORM
DESCRIPTION

1ST-501

AI Drug Discovery Engine

Drug engineering platform leveraging Medchem expertise and advanced AI technology / Discovery

1ST-FINDERTM

TPD

Targeted Protein Degradation, FINDER (Firstbio INDuced proximity discovERy) / Discovery
Discovery
Preclinical
Phase 1